| Name: | Atorvastatin-FX1 Impurity(Na Salt) |
| Catalogue No. | VL10021 |
| CAS No. | 1315629-79-8 |
| Molecular Formula | C33H34FN2O7.Na |
| Molecular Weight | 590.64g/mol (Acid); 612.22g/mol (Na Salt) |
| Status | In-stock |
| IUPAC Name | 4-(1b-(4-fluorophenyl)-7-hydroxy-7-isopropyl-1a-phenyl-7a- (phenylcarbamoyl)hexahydro-1aH-oxireno[2’,3’:3,4]pyrrolo[2,1- b][1,3]oxazin-3-yl)-3-hydroxybutanoic acid Sodium salt |
| Synonyms | Atorvastatin Cyclic Fluorophenyl (Cyclo FP) / Atorvastatin Epoxy Pyrrolooxazin 7-Hydroxy analog |
| Description | Atorvastatin Cyclic Fluorophenyl (Cyclo FP) / Atorvastatin Epoxy Pyrrolooxazin 7-Hydroxy analog (CAS No: 1315629-79-8)or 4-(1b-(4-fluorophenyl)-7-hydroxy-7-isopropyl-1a-phenyl-7a- (phenylcarbamoyl)hexahydro-1aH-oxireno[2’,3’:3,4]pyrrolo[2,1- b][1,3]oxazin-3-yl)-3-hydroxybutanoic acid Sodium salt is an impurity of atorvastatin. it is highly plasma protein bound (over 98%) and has a volume of distribution of about 380 liters and metabolized by cytochrome P450 3A4 (CYP3A4) to active ortho- and para |
| References | McIver, Lindsey A., and Momin S. Siddique. “Atorvastatin.” Nih.gov, StatPearls Publishing, 5 Jan. 2019, www.ncbi.nlm.nih.gov/books/NBK430779/. Black, Donald M., et al. “An Overview of the Clinical Safety Profile of Atorvastatin (Lipitor), a New HMG-CoA Reductase Inhibitor.” Archives of Internal Medicine, vol. 158, no. 6, Mar. 1998, p. 577, https://doi.org/10.1001/archinte.158.6.577. |
